These targeted agents have received FDA approval for treating KRAS G12C–mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC), with sotorasib approved in May 2021 and adagrasib following in December 2022 [1, 2]. This evidence concerns the gene KRAS and colorectal carcinoma.